Barclays analyst Peter Lawson reiterates an Overweight rating on Geron (GERN) with a $9 price target following a transfer of coverage. The firm increased its Q4 revenue estimate to $45.0M, above the consensus of $43.3M, to reflect “encouraging” commercial launch execution. Longer term, it sees potential from label expansion into new indications like myelofibrosis.
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GERN:
- Geron Corporation’s Q3 2024: Strong RYTELO Launch and Financial Growth
- Geron price target raised to $9 from $8 at H.C. Wainwright
- Geron announces $375M in synthetic royalty, debt financings with Royalty Pharma
- Royalty Pharma to acquire royalty interest in Geron’s RYTELO for $125M
- Geron reports Q3 EPS (4c), consensus (8c)